Spore.Bio
Paris
About Spore.Bio
Spore.Bio develops technology for rapid microbiology testing that uses light-based sensing and AI to detect and quantify microbial contamination in products across industries like food, beverages, cosmetics, pharmaceuticals, and water systems. The company’s platform combines machine learning models with photonic data to produce near-real-time insights about bacterial presence without the long incubation times required by traditional lab methods. Spore.Bio also integrates testing hardware with analytical dashboards that help quality teams monitor contamination trends and process data. The firm collaborates with scientific partners to expand its microbial datasets and continuously refine detection models. Its offerings aim to support manufacturers in transitioning from delayed lab testing toward faster contamination awareness and response.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $31.6M
- Funding stage: Early Stage Venture
- Last round: Grant (Jan 2026)
- Website: spore.bio
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Industrial Manufacturing, Information Technology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/spore-bio-51787 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.